Abstract:
Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using the 4-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as cerebral ischemia, central nervous system trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headaches, convulsions, aminoglycoside antibiotics-induced hearing loss, chronic pain, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, urinary incontinence and neurodegenerative disorders such as lathyrism, Alzheimers' Disease, Parkinsonism, and Huntington's Disease are described. Also described are novel methods for preparing 4-substituted piperidine analogs and novel intermediates of the 4-substituted piperidine analogs.
Abstract:
Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headaches, glaucoma, CMV retinitis, chronic pain, opioid tolerance or withdrawals, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described. Also described are novel methods for preparing 4-substituted piperidine analogs and novel intermediates of the 4-substituted piperidine analogs.
Abstract:
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia, and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment or prevention a substituted or unsubstituted pyridine and pyridine (N-oxide) analogs of 4-hydroxydihydroquinolones, tetrahydroquinoline-trione-oximes and quinoxalones, tautomers and pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
Abstract:
The present disclosure is related to coated photoconductors. In an example, a coated photoconductor can comprise a photoconductor including a substrate having a charge generation layer and charge transport layer adhered thereto and a top coating adhered to the photoconductor. The top coating can comprise a cross-linkable polymer, a cross-linker, and a polymeric dopant having a weight average molecular weight of less than 500,000. Additionally, the top coating can have a thickness of 0.1 μm to 12 μm and the polymeric dopant can be present in the top coating at a concentration of 0.1 wt % to 10 wt %.
Abstract:
Surfactants are provided that have a hydrophobic tail portion and a hydrophilic head portion. The hydrophilic head portion includes a terminal dialkyl-substituted tertiary amine or a terminal cycloalkyl-substituted tertiary amine. Also provided are pigment-based inks employing the surfactant, a combination of an electronic display and the pigment-based inks, and a process for reducing conductivity in primary amine-based surfactants and improving reliability of electronic inks employing such surfactants.
Abstract:
Pigment based inks are provided. The inks include a non-polar carrier fluid and a surface-functionalized pigment particle including a nitrogen-linked moiety to the surface of the pigment particle through a nitrogen link at one end of the nitrogen-linked moiety and a graft copolymer having two or three blocks attached at another end, the pigment particle suspended in the non-polar carrier fluid, the nitrogen-linked moiety further including an alkyl chain interposed between the nitrogen-linked moiety and the graft copolymer having the structure (I), where X is the nitrogen-linked moiety and Y is a copolymer, and the letter a is an integer between 0 and about 5,000, while the letter b is an integer of 2 or more.
Abstract:
An alcohol-soluble organic coating including a hole transport material formed on a surface of organic photoconductor is provided. The coating comprises a cationic alternate fluorene-based copolymer with phosphonium salt terminal groups embedded in an in-situ cross-linked polymer.
Abstract:
An organic photoconductor includes: a conductive substrate; a charge generation layer on the conductive substrate; and a charge transport layer on the charge generation layer. An overcoat layer is formed on the charge transport layer. The overcoat layer is a latex polymer in which a charge transport material is dispersed.
Abstract:
A doped protective coating for extending a lifetime of an organic photoconductor is provided. The coating includes an in-situ cross-linked polymer matrix and a substantially uniformly distributed dopant therein. The dopant comprises a charge transport molecular species. A process for coating the organic photoconductor and a coated organic photoconductor are also disclosed.
Abstract:
Electronic inks are disclosed herein. The electronic ink includes a non-polar carrier fluid, a plurality of positively charged colorant particles dispersed in the non-polar carrier fluid, and a plurality of reverse co-micelles including a basic charge director and an acidic charge controlling agent. The basic charge director has a molecular weight that is within 5000 of a molecular weight of the acidic charge controlling agent.